Skip to main
ONCY
ONCY logo

ONCY Stock Forecast & Price Target

ONCY Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncolytics Biotech Inc is strategically focused on developing innovative cancer therapies, particularly through its leading candidate, pelareorep, which enhances immune response against tumors. The potential for partnerships in advancing pelareorep toward regulatory approval could significantly extend the company's operational capacity and unlock substantial shareholder value. Additionally, external validation from key opinion leaders bolsters Oncolytics' positioning for collaboration, reinforcing the long-term commercial viability of its immunotherapeutic pipeline.

Bears say

Oncolytics Biotech Inc. faces significant challenges due to its status as a clinical-stage biopharmaceutical company, which entails substantial financial risk associated with ongoing research and development efforts without guaranteed future revenue. The company's reliance on a limited pipeline of projects, including pelareorep and several cohort studies, raises concerns about its ability to achieve successful clinical outcomes, potentially limiting its market viability. Furthermore, the extended timeline required for drug development and the competitive landscape within the oncology sector may further hinder its financial performance and investor confidence.

ONCY has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncolytics Biotech, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncolytics Biotech, Inc. (ONCY) Forecast

Analysts have given ONCY a Strong Buy based on their latest research and market trends.

According to 4 analysts, ONCY has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncolytics Biotech, Inc. (ONCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.